Nucleotide and amino acid sequences (Form 1200, Section 9) 
5.6.006
Where the Euro-PCT application discloses nucleotide or amino acid sequences, a sequence listing in electronic form drawn up in compliance with the applicable WIPO standard must be available to the EPO as a designated/elected Office on expiry of the 31-month time limit. For international applications filed up until 30 June 2022, WIPO Standard ST.25 is applicable; for international applications filed on or after 1 July 2022, WIPO Standard ST.26 is applicable. Extensive information about sequence listing Standard ST.25 is provided in the notice from the EPO dated 18 October 2013. Details of the practice which will be applied for applications filed on or after 1 July 2022 are provided in the decision of the President of the EPO dated 9 December 2021 on the filing of sequence listings and the explanatory notice from the EPO (see OJ 2021, A96 and A97). The sequence listing must be filed in electronic format only; consequently, a sequence listing filed on paper or in PDF format will be disregarded. The following paragraphs describe the practice applicable for international applications filed up until 30 June 2022.
5.6.007
As a rule, the required sequence listing will be available to the EPO if it was contained in the international application under Rule 5.2 PCT or filed under Rule 13ter PCT with the EPO acting as ISA/SISA or IPEA (see points 2.23.001 ff). Further, it will also be accessible to the EPO if it is made available by WIPO on PATENTSCOPE and can be downloaded in a usable form.
5.6.008
The applicant should in due time verify whether the sequence listing is available to the EPO in the required form and, if it is not, file it before expiry of the 31-month time limit in electronic (TXT) format, preferably via one of the EPO's online filing tools (Online Filing or Online Filing 2.0) or, if not, on a data carrier. 
5.6.009
If a sequence listing must be filed upon entry into the European phase, the applicant must enclose a statement to the effect that the information contained in the sequence listing does not go beyond the content of the original application documents. This statement can be made by crossing the appropriate box in Section 9.2 of Form 1200. 
5.6.010
A translation of any free text in a sequence listing which forms part of the description or which was filed subsequently need only be provided if it is not yet available to the EPO in English (see point 5.5.011). If text matter in a sequence listing must be translated, the complete sequence listing complying with WIPO Standard ST.25, including the translated text matter, must be submitted.

Quick Navigation